Abstract
BJU InternationalVolume 113, Issue 4 p. 654-655 Translational Science What next for phosphodiesterase inhibitor failures? Michael G. Wyllie, Corresponding Author Michael G. Wyllie Plethora Solutions Ltd London, London, UK Correspondence: Michael G. Wyllie, Plethora Solutions Ltd, Stratton House, 3 Marshalls Close, Shenington, Oxford OX15 6ND, UK. e-mail: m.wyllie@globalpharma.co.ukSearch for more papers by this author Michael G. Wyllie, Corresponding Author Michael G. Wyllie Plethora Solutions Ltd London, London, UK Correspondence: Michael G. Wyllie, Plethora Solutions Ltd, Stratton House, 3 Marshalls Close, Shenington, Oxford OX15 6ND, UK. e-mail: m.wyllie@globalpharma.co.ukSearch for more papers by this author First published: 21 January 2014 https://doi.org/10.1111/bju.12636Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume113, Issue4April 2014Pages 654-655 RelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
